CLEARER DISEASE DIAGNOSIS
symptoms than people with AD who test negative for alpha-synuclein.
THE MICHAEL J. FOX FOUNDATION 2025 YEAR IN REVIEW
Researchers are also looking at people with Parkinson’ s, including participants in the Foundation’ s landmark Parkinson’ s Progression Markers Initiative study, to see if biomarkers linked to AD are present in some individuals and how this might impact Parkinson’ s symptoms and progression. Results from these studies could potentially guide future treatments: It may even be that drugs approved for Alzheimer’ s may hold benefits for some people with PD— and vice versa.
Parkinson’ s Therapies in Development Target Varied Disease Biology
An enhanced understanding of the role different underlying causes play in disease progression has unlocked a world of treatment possibilities. Drugs in development target a variety of biologic mechanisms associated with PD, with the goal of delivering personalized medicine.
7